Document Classification

Section Type: METHODS

Text: Younger untreated patients with AML (median age, 49 years ; range, 0 to 73 years) were randomly allocated to two induction courses of daunorubicin and cytarabine (DA) with or without etoposide (ADE ; n = 1983) or ADE versus fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-Ida ; n = 1268), and to amsacrine, cytarabine, etoposide, and then mitoxantrone/cytarabine (MACE-MidAC) or high-dose cytarabine (n = 1, 445) 3 g/m (2) or 1. 5 g/m (2) (n = 657) in consolidation, and finally to a fifth course (cytarabine) or not (n = 227).